6-methylheptyl 3-(4-hydroxy-3-methoxyphenyl)propionate | 951221-90-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 6-methylheptyl 3-(4-hydroxy-3-methoxyphenyl)propionate
• 英文别名: 6-Methylheptyl 3-(4-hydroxy-3-methoxyphenyl)propanoate
• CAS: 951221-90-2
• 化学式: C₁₈H₂₈O₄
• 分子量: 308.418
• InChiKey: HQHRNVGMRBJTMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• ESTER DERIVATIVE AND USE THEREOF
  申请人：AMINO Yusuke

  公开号：US20090170942A1

  公开（公告）日：2009-07-02

  A compound represented by the following formula (I′) wherein X 1 is a methylene group, an ethylene group, a trimethylene group or a vinylene group, X 2 is a divalent group represented by the following formula A or B, Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X 1 is a methylene group, then X 2 is not a divalent group represented by the formula A, and when X 1 is a vinylene group, then X 2 is not a divalent group represented by the formula A. The compound is a stable capsinoid derivative, and is useful as an active ingredient of an external blood circulation enhancer or a cosmetic composition, a pharmaceutical composition, or a food composition.

  以下式(I')表示的化合物 其中X1是亚甲基基团，亚乙基基团，亚丙基基团或乙烯基基团，X2是由以下式A或B表示的二价基团， Y是亚乙基基团或乙烯基基团，m和n都是0到7的整数，满足m+n=0到8，R1和R2各自独立为氢原子，甲基基团或乙基基团，条件是当X1是亚甲基基团时，那么X2不是由式A表示的二价基团，并且当X1是乙烯基基团时，那么X2不是由式A表示的二价基团。该化合物是一种稳定的辣椒素衍生物，并且作为外周血液循环增强剂，化妆品组合物，药物组合物或食品组合物的有效成分是有用的。
• NOVEL ESTER DERIVATIVE AND USE THEREOF
  申请人：AMINO YUSUKE

  公开号：US20130053441A1

  公开（公告）日：2013-02-28

  A compound represented by the following formula (I′) wherein X 1 is a methylene group, an ethylene group, a trimethylene group or a vinylene group, X 2 is a divalent group represented by the following formula A or B, Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X 1 is a methylene group, then X 2 is not a divalent group represented by the formula A, and when X 1 is a vinylene group, then X 2 is not a divalent group represented by the formula A. The compound is a stable capsinoid derivative, and is useful as an active ingredient of an external blood circulation enhancer or a cosmetic composition, a pharmaceutical composition, or a food composition.

  化合物的化学式如下（I′），其中X1是一个亚甲基基团，乙烯基团，三亚甲基基团或乙烯基基团，X2是由以下公式A或B表示的二价基团，Y是乙烯基团或乙烯基基团，m和n分别为0到7的整数，满足m+n=0到8，R1和R2分别是氢原子，甲基基团或乙基基团，但当X1是亚甲基基团时，X2不是由公式A表示的二价基团，当X1是乙烯基基团时，X2不是由公式A表示的二价基团。该化合物是一种稳定的辣椒素类衍生物，可用作外用血液循环增强剂或化妆品组合物、药用组合物或食品组合物的活性成分。
• US8212068B2
  申请人：——

  公开号：US8212068B2

  公开（公告）日：2012-07-03
• US8765809B2
  申请人：——

  公开号：US8765809B2

  公开（公告）日：2014-07-01
• [EN] MEANS AND METHODS FOR ASSESSING LIVER TOXICITY<br/>[FR] MOYES ET PROCÉDÉS D'ESTIMATION DE LA TOXICITÉ HÉPATIQUE
  申请人：BASF SE

  公开号：WO2009153136A2

  公开（公告）日：2009-12-23

  The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver toxicity. It also relates to a method of determining whether a compound is capable of inducing such liver toxicity in a subject and to a method of identifying a drug for treating liver toxicity. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing liver toxicity. Finally, the present invention- pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing liver toxicity in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver toxicity markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, Hydroxyphenylpyruvic acid, alpha-Tocopherol, Cholesterol,myo-Inositol-2-monophosphate, 4-Hydroxysphinganine, Ceramide (dl8:1, C24:1), Ceramide (dl8:2, C24:0), Sphingomyelin (dl8:1, C16:0), 1, 2-Dioleoyl-sn-glycero-3-phosphatidyl-L-serine, 18:1 Lyso Phosphatidylcholine, CoenzymeQ9, Glucose, Glycerol, Glycerophosphates, Phosphate, 5-Methoxysphingosine, erythrosphingosine, Threonine, Diacylglycerides and Triacylglycerides.